E018 Long-term effects of fosinopril on target organ damage in hypertensive patients

l

A

X

A

B

O

S

I

T

E

S

R

AI 1

A

1 CN 9 4 PH

]

2 AT 9 H

E

AN E E v H

M D B

Q

v

B

c a f

w

I

(

c s

6

s s

c

f

A(

v

n

a l

mtig

5 w

w o a

v

s

v

a

i

1

a o

s

b

m

t

s

( 1+ 1O N E w m L( w a concomitant larger A + 1+0.5”/. b a a

7)t .

(

increase

t

w m

t d

w

a s p

w

m m

(

w

d

w

0

o

s m

(

o

d

a

b

E

( t

p

a

d

a

j

p t

e

4

reduction

( 164+3/103+1

to

14S+3/91+1

on A vs 161+3/104+1

clear-cut b

and t

b a

+ 2 (

w p

v

d

e

a

+ n

e v

% (P=O.0S2),

a v d

h

%

e

t

t

p 1

%c +0.4+0.3

m

Words:

Calcium

entry

f

T A

e

o ln

i

i

w

(

i

ne

d

I

t s

m o

C

a

e

s

e

b t T

o

a

3

f w

w

a

g

B

s l

f

d

o

a

y

p

W

l l

n

u

s m

w

f

O

s

c eh

t

p

( t g d 1 r d t a e

o

%

a U

e

i

f a

I

r

y

s

v I

i

m

i

I

2

w

b T

e

a 1

m

h

e m

s

e

t

t

0

U 3

e

O

a e

h

t

u

s

d

o

f

a

accurately

measuring

q

a C

s

e

blockers,

A M

T

t i K

K

I

U N

(all NS), azrd 0.6*0.3

In conclusion,

a

1

p a

+0.4+0.3,

o t r

d

i

s

respectively.

s

r

1 T

e

+0.3+0.3,

i

+

s

w

w

t

a

w

min was

d

to 149+3/95+1 on L). There was a (P
significant

S

r e r f E p s ( h a s h A g m T

w

d

(

A s

h

t

a

v

a p

e

d

d

f

m

H

O I

K

U

a for the

m h

F

F I

N

(

o

a

e

b

L D M B U

C

HW van Hanrersvelt

V

p

T

d r

I T

e

l

T

N t

R

e 0

A W

Andresdottir,

H

v t

F C W

U

f

edema,

v

W

M

e

E

i

h

E

E

a

t p

s

t

1 w

f

c

h 2

t

v p

C i

D

V

m

D G Beevers”, ‘ D ““”Reha-Zentrum

M Gallet””, M Middeke””, M B Spreewald, B # K

T Notter# “ L

P Z S Joseph,

T

A

b c

t t

2 g t

(

4

r

T

r

t

p W

3 C

C

H

r

c

a

d

e

mg/day)

y h h

a

s

i

w

w

a

H

v

l

0

H

a

h

d

(

d T t t

N

r

n

e

m t

v

c

t

t

w

M

R t

t l

p

f w

D

n

( s

t

w

t

s b

e a

s

a

a

f c

d c

may p t

f w

tt

t i

i

h o

w IS

K

W

c s

T

w n

H

N

4 H

h

t

d a H

c w

i

e c

t H

(

r

u

m

( f

p

D

p

f

d L

d m

A u

t

e

u a

d

N

m

l

h

c

a

r

(

r D

t

I

o

o n

(NIF:20-40

p

e b

s

nifediplne

u

p

a

H

n

w R HRV of both slow-release

h

d

S

c

manner

r

U

i e

and slow-release

o

Y

H

e

u

2

m 0

e

crossover c

w

t c

(

bllnd

f

a

H

c

d

y n r

r K K

a n

t

in a single

<

U

m

h

R r

K

(

(DLT:1OO-2OO mg/day)

h p

U

ap m

H H

S

v

n

diltizem

N

U H

Y

a

o h

W

S

Lyon

P g t s w e t a e a s v S 1 ( o d m p ( i p o 5 w w t 2 ( m T m m p r d b ( a p g . c t d p S b ( p r w I T t w a I V T t ( w A t 8 p m 3 c w e m t p r p t 6 p e t T t p O t 3 p ( T m ( b p a m a d 6 8 $ 5m w r a r V T od f w B p g w w m f a h w a b D t e t T p n t g p l r V b D r w 1 m a 1 m t g l r T A w t D w l 9 m ( m n t V g a 9 m ( 3 m t T g ( 0 A m r s I w 8 2 m t V a O6 m t T g b h s s ( 0 2 ( 6 p w e t T p r 4 a e ( E D t p 2 A w r 1 ( p H ( V 6 c ( n V n a c ( , V n w ~ c m r d t r

A

P M

K

O

a

h n

r

v

a r

l